Log in with your email address username.


[Correspondence] Men B: lack of coverage or vaccine failure?

In the UK, a substantial reduction of cases of serogroup B (MenB) meningococcal disease in infants is anticipated following the introduction of Bexsero (GlaxoSmithKline) into the infant immunisation schedule. This vaccine is not, however, a panacea. Strain coverage is estimated at 88% for UK MenB strains,1 allowing for the possibility of MenB disease in Bexsero-immunised individuals due to strains not covered by the vaccine (appendix).